Table 4.

Treatment decisions in case 1.

Induction of remission (Q14)
1	Intravenous Methylprednisolone (IVMP) over 5 days, followed by oral prednisolone	68/73	93.2%
2	Intravenous Cyclophosphamide every month for 4-6 months	47/73	64.3%
3	Mycophenolate mofetil (MMF)	9/73	12.3%
4	Oral prednisolone	3/73	4.1%
Prophylaxis of thromboembolic events (Q15)
1	IV heparin initially	46/70	65.7%
2	Acetyl salicylic acid (ASA)	19/70	27.1%
3	Combination of ASA and clopidogrel	5/70	7.1%
4	“Others”: including low molecular weight heparin, Heparin 100 IU/kg/12hr	13/70	18.6%
-	Warfarin, clopidogrel alone or direct oral anticoagulants (DOAC);	0	0
Post-acute phase thrombosis prophylaxis (Q16)
1	ASA	33/70	47.1%
2	Subcutaneous heparin	16/70	22.9%
3	Combination of ASA and clopidogrel	10/70	14.3%
4	Warfarin	8/70	11.4%
5	Clopidogrel	4/70	5.7%
6	DOACs	2/70	2.9%
7	None	1/70	1.4%
Duration of thrombosis prophylaxis (Q17)
	3 months	7/70	10%
	6 months	9/70	12.9%
	12 months	13/70	18.6%
	18 months	3/70	4.3%
	24 months	13/70	18.6%
	36 months	9/70	12.9%
	None	1/70	1.4%
Immune modulating maintenance treatment (Q18)
1	MMF	53/73	72.6%
2	Azathioprine	15/73	20.5%
3	Oral prednisolone	13/73	17.8%
4	Oral cyclophosphamide (following Fauci scheme)	1/73	1.4%
4	TNF inhibitors	1/73	1.4%
Duration of immune modulating treatment (Q19)
	3 months	3/73	4.1%
	6 months	4/73	5.5%
	12 months	12/73	16.4%
	18 months	14/73	19.2%
	24 months	27/73	37.0%
	36 months	4/73	5.5%
Duration of oral corticosteroid treatment, including slow taper (Q20)
	3 months	15/72	20.8%
	6 months	30/72	41.7%
	12 months	11/72	15.3%
	18 months	3/72	4.2%
	24 months	4/72	5.6%
	36 months	1/72	1.4%
	None	1/72	1.4%